CD8-Positive T-Lymphocytes
"CD8-Positive T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
| Descriptor ID |
D018414
|
| MeSH Number(s) |
A11.118.637.555.567.569.220 A15.145.229.637.555.567.569.220 A15.382.490.555.567.569.220
|
| Concept/Terms |
CD8-Positive T-Lymphocytes- CD8-Positive T-Lymphocytes
- CD8 Positive T Lymphocytes
- CD8-Positive T-Lymphocyte
- T-Lymphocyte, CD8-Positive
- T-Lymphocytes, CD8-Positive
- T8 Lymphocytes
- Lymphocyte, T8
- Lymphocytes, T8
- T8 Lymphocyte
- T8 Cells
- Cell, T8
- Cells, T8
- T8 Cell
- CD8-Positive Lymphocytes
- CD8 Positive Lymphocytes
- CD8-Positive Lymphocyte
- Lymphocyte, CD8-Positive
- Lymphocytes, CD8-Positive
Suppressor T-Lymphocytes, CD8-Positive- Suppressor T-Lymphocytes, CD8-Positive
- CD8-Positive Suppressor T-Lymphocyte
- CD8-Positive Suppressor T-Lymphocytes
- Suppressor T Lymphocytes, CD8 Positive
- Suppressor T-Lymphocyte, CD8-Positive
- T-Lymphocyte, CD8-Positive Suppressor
- T-Lymphocytes, CD8-Positive Suppressor
- Suppressor T-Cells, CD8-Positive
- CD8-Positive Suppressor T-Cell
- CD8-Positive Suppressor T-Cells
- Suppressor T Cells, CD8 Positive
- Suppressor T-Cell, CD8-Positive
- T-Cell, CD8-Positive Suppressor
- T-Cells, CD8-Positive Suppressor
|
Below are MeSH descriptors whose meaning is more general than "CD8-Positive T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "CD8-Positive T-Lymphocytes".
This graph shows the total number of publications written about "CD8-Positive T-Lymphocytes" by people in this website by year, and whether "CD8-Positive T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 4 | 4 |
| 1995 | 2 | 8 | 10 |
| 1996 | 3 | 3 | 6 |
| 1997 | 3 | 4 | 7 |
| 1998 | 4 | 7 | 11 |
| 1999 | 5 | 5 | 10 |
| 2000 | 5 | 10 | 15 |
| 2001 | 4 | 4 | 8 |
| 2002 | 10 | 6 | 16 |
| 2003 | 11 | 11 | 22 |
| 2004 | 9 | 10 | 19 |
| 2005 | 18 | 8 | 26 |
| 2006 | 18 | 9 | 27 |
| 2007 | 15 | 16 | 31 |
| 2008 | 13 | 11 | 24 |
| 2009 | 20 | 11 | 31 |
| 2010 | 9 | 15 | 24 |
| 2011 | 16 | 9 | 25 |
| 2012 | 14 | 14 | 28 |
| 2013 | 17 | 9 | 26 |
| 2014 | 16 | 19 | 35 |
| 2015 | 10 | 8 | 18 |
| 2016 | 12 | 12 | 24 |
| 2017 | 19 | 15 | 34 |
| 2018 | 14 | 20 | 34 |
| 2019 | 24 | 25 | 49 |
| 2020 | 16 | 29 | 45 |
| 2021 | 19 | 34 | 53 |
| 2022 | 13 | 32 | 45 |
| 2023 | 11 | 29 | 40 |
| 2024 | 12 | 22 | 34 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD8-Positive T-Lymphocytes" by people in Profiles.
-
Histone lactylation drives CD8+ T cell metabolism and function. Nat Immunol. 2024 Nov; 25(11):2140-2151.
-
Astrocyte-induced Cdk5 expedites breast cancer brain metastasis by suppressing MHC-I expression to evade immune recognition. Nat Cell Biol. 2024 Oct; 26(10):1773-1789.
-
CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia. Blood. 2024 09 12; 144(11):1168-1182.
-
Assessing clonal changes in T?cells over time following immunotherapy is a breeze with Cyclone. Cancer Cell. 2024 Sep 09; 42(9):1491-1493.
-
Therapeutic vaccine targeting dual immune checkpoints induces potent multifunctional CD8+ T cell anti-tumor immunity. Int Immunopharmacol. 2024 Dec 05; 142(Pt A):113004.
-
Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fc? receptors during acute SHIVAD8-EO infection. Nat Commun. 2024 Aug 29; 15(1):7461.
-
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors. J Immunother Cancer. 2024 Aug 28; 12(8).
-
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. J Exp Med. 2024 Oct 07; 221(10).
-
LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8+ T cell responsiveness. Nat Commun. 2024 Aug 27; 15(1):7366.
-
Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. Cell. 2024 Aug 08; 187(16):4373-4388.e15.